MDSCs in sepsis-induced immunosuppression and its potential therapeutic targets
Copyright © 2022. Published by Elsevier Ltd..
Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. In sepsis, a complicated immune response is initiated, which varies over time with sustained excessive inflammation and immunosuppression. Identifying a promising way to orchestrate sepsis-induced immunosuppression is a challenge. Myeloid-derived suppressor cells (MDSCs) comprise pathologically activated neutrophils and monocytes with potent immunosuppressive activity. They play an important part in inhibiting innate and adaptive immune responses, and have emerged as part of the immune response in sepsis. MDSCs numbers are persistently high in sepsis patients, and associated with nosocomial infections and other adverse clinical outcomes. However, their characteristics and functional mechanisms during sepsis have not been addressed fully. Our review sheds light on the features and suppressive mechanism of MDSCs. We also review the potential applications of MDSCs as biomarkers and targets for clinical treatment of sepsis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:69 |
|---|---|
| Enthalten in: |
Cytokine & growth factor reviews - 69(2023) vom: 02. Feb., Seite 90-103 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Wanying [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 07.02.2023 Date Revised 24.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cytogfr.2022.07.007 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344466884 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344466884 | ||
| 003 | DE-627 | ||
| 005 | 20231226022835.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cytogfr.2022.07.007 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1148.xml |
| 035 | |a (DE-627)NLM344466884 | ||
| 035 | |a (NLM)35927154 | ||
| 035 | |a (PII)S1359-6101(22)00056-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Wanying |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a MDSCs in sepsis-induced immunosuppression and its potential therapeutic targets |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.02.2023 | ||
| 500 | |a Date Revised 24.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022. Published by Elsevier Ltd. | ||
| 520 | |a Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. In sepsis, a complicated immune response is initiated, which varies over time with sustained excessive inflammation and immunosuppression. Identifying a promising way to orchestrate sepsis-induced immunosuppression is a challenge. Myeloid-derived suppressor cells (MDSCs) comprise pathologically activated neutrophils and monocytes with potent immunosuppressive activity. They play an important part in inhibiting innate and adaptive immune responses, and have emerged as part of the immune response in sepsis. MDSCs numbers are persistently high in sepsis patients, and associated with nosocomial infections and other adverse clinical outcomes. However, their characteristics and functional mechanisms during sepsis have not been addressed fully. Our review sheds light on the features and suppressive mechanism of MDSCs. We also review the potential applications of MDSCs as biomarkers and targets for clinical treatment of sepsis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a MDSCs | |
| 650 | 4 | |a MDSCs‐targeting therapy | |
| 650 | 4 | |a Sepsis | |
| 650 | 4 | |a Sepsis-induced immunosuppression | |
| 700 | 1 | |a Fang, Xiangzhi |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Chenggang |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Chaoying |e verfasserin |4 aut | |
| 700 | 1 | |a He, Yajun |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Ting |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Xiaobo |e verfasserin |4 aut | |
| 700 | 1 | |a Shang, You |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Jiqian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cytokine & growth factor reviews |d 1996 |g 69(2023) vom: 02. Feb., Seite 90-103 |w (DE-627)NLM088318842 |x 1879-0305 |7 nnns |
| 773 | 1 | 8 | |g volume:69 |g year:2023 |g day:02 |g month:02 |g pages:90-103 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cytogfr.2022.07.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 69 |j 2023 |b 02 |c 02 |h 90-103 | ||